Disordered sensory gating of the P50 component of the auditory evoked potentials (AEP);Zaburzenia bramkowania składowej P50 słuchowych potencjałów wywołanych-neurobiologia filtrów informacyjnych i ich dysfunkcja w schizofrenii

Psychiatria Polska

Volumn 38, Issue 5, 2004, Pages 833-845

  Wȩgrzyn, Jacek ^a  

^a III Klinika IPiN   (Poland)

Author keywords

Auditory evoked potentials; P50; Sensory gating

Indexed keywords

BRAIN FUNCTION; EVOKED AUDITORY RESPONSE; EVOKED RESPONSE; HUMAN; MENTAL DISEASE; NEUROPHYSIOLOGY; PATHOPHYSIOLOGY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SENSORY GATING;

AUDITORY PATHWAYS; CEREBRAL CORTEX; EVOKED POTENTIALS, AUDITORY; EVOKED POTENTIALS, SOMATOSENSORY; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, NEUROLOGICAL; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX;

EID: 6444226028     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Shakow D. Kent-Rosanoff association test and its implications for segmental set theory. Schizophr. Bull. 1980; 6, 4: 676-685.
2. Broadbent DE. Perception and communication. New York: Pergamon; 1958.
3. Broadbent DE. Decision and stress. London: Academic Press; 1971.
4. Umilta C. Orienting and attention. Handbook of neuropsychology, vol. 1. Amsterdam, New York, Oxford: Elsevier, 1994, s. 175-193.
5. Van Zomeren AH, Brouwer WH. Clinical neuropsychology of attention. New York, Oxford: Oxford Univ. Press; 1994.
6. Wrońska A. Współczesne pogla̧dy na procesy pamiȩci i uwagi u chorych na schizofreniȩ. Farmakoter. Psychiatr. Neurol. 1998; 4: 42-50.
7. Baddeley AD. Working memory. Oxford: Clarendon; 1986.
8. Randolph Ch, Goldberg TE, Weinberger DR. The neuropsychology of schizophrenia. W: Heilmann K, Valenstein E, red. Clinical neuropsychology. Oxford Univ. Press; 1993, s. 499-521.
9. Goldberg TE, Hyde TH, Kleinman JE, Weinberger DR. Course of schizophrenia: neuropsychological evidence for a static encephalopathy. Schizophr. Bull. 1993; 19: 797-804.
10. Goldberg TE, Ragland JD, Torrey EF, Gold JM, Bigelow LB, Weinberger DR. Neuropsychological assesment of monozygotic twins discordant for schizophrenia. Arch. Gen. Psychiatry 1990; 47: 1066-1072.
11. Fleming K, Goldberg TE, Gold JM. Applying working memory constructs to schizophrenic cognitive impairment. W: David AS, Cutting JC. The neuropsychology of schizophrenia. Hove (UK), Hillsdale (USA): 1994, s. 197-208.
12. Weinberger DR, Gallhoffer B. Cognitive function in schizophrenia. Int. Clin. Psychopharmacol. 1997, 12 (supl. 4): 29-36.
13. Knott V, Mahoney C, Labelle A, Ripley C, Cavazzoni P, Jones B. Event-related potentials in schizophrenic patients during a degraded stimulus version of the visual continuous performance task. Schiz. Res. 1999; 35, 3: 263-278.
14. Payne RW Cognitive abnormalities. W: Eysenck HJ, red. Handbook of abnormal psychology. New York: Basic Books; 1961, s. 193-261.
15. McGhie A, Chapman JS. Disorders of attention and perception in early schizophrenia. Brit. J. Med. Psychol. 1961; 34: 103-115.
16. Payne RW, Matussek P, George EI. An experimental study of schizophrenic taught disorder. J. Ment. Sc. 1959; 105: 627-639.
17. McGhie A. Attention and perception in schizophrenia. W: Maher BA, red. Progress in experimental personality research. Vol. 5. New York: Academic Press; 1970, s. 1-38.
18. Venables PH. Input dysfunction in schizophrenia. W: Maher BA, red. Progress in experimental personality research. Vol. 1. New York: Academic Press; 1964, s. 1-48.
19. Freedman R, Adler LE, Gerhardt GA, Waldo M, Baker N, Rose GM, Drebing C, Nagamoto H, Bickford-Wimer P, Franks R. Neurobiological studies of sensory gating in schizophrenia. Schizophr. Bull. 1987; 13: 4669-4678.
20. Ecless JC. The inhibitory pathways of the central nervous system. Springfield, IL: Charles C. Thomas; 1969.
21. Davis H, Mast T, Yoshie N, Zerlin S. The slow response of the human cortex to auditory stimuli: recovery cycle proces. Electroenceph. Clin. Neurophysiol. 1966; 21: 105-113.
22. Adler LE, Rose GM, Freedman R. Neurophysiological studies of sensory gating in rats: effect of amphetamine, phencyclidyne, and haloperidol. Biol. Psychiatry 1986; 21: 787-798.
23. Roth WT, Kopell BS. The auditory evoked response to repeated stimuli during a vigilance task. Psychophysiol. 1969; 6: 301-309.
24. Siegel C, Waldo M, Mizner G, Adler LE, Freedman R. Deficits in sensory gating in schizophrenic patients and their relatives. Evidence obtained with auditory evoked responses. Arch. Gen. Psychiatry 1984; 41: 6607-6612.
25. Adler LE, Pachtman E, Franks RD, Pecevich M, Waldo MC, Freedman R. Neurophysiological evidence for a defect in neuronal mechanisms in sensory gating in schizophrenia. Biol. Psychiatry 1982; 17: 639-654.
26. Freedman R, Adler LE, Waldo MC, Pachtman E, Franks RD. Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparision of medicated and drug free patients. Biol. Psychiatry 1983; 18: 537-551.
27. Nagamoto HT, Adler LE, Waldo MC, Griffith J, Freedman R. Gating of auditory response in schizophrenics and normal controls. Effects of recording site and stimulation interval on the P50 wave. Schiz. Res. 1991; 4: 31-40.
28. Erwin RJ, Buchwald JS. Midlatency auditory evoked responses: Differential recovery cycle characteristics. Electroencephal. Clin. Neurophysiol. 1986; 64: 417-423.
29. Jerger K, Biggins Ch, Fein G. P50 supression is not affected by attentional manipulations. Biol. Psychiatry 1992; 31: 365-377.
30. Papanicolau AC, Loring DW, Eisenberg HM. Evoked potential attenuation in two-tone paradigm. Int. J. Psychobiol. 1985; 3: 23-28.
31. Cardenas VA, Gill P, Fein G. Human P50 suppression is not affected by variations in wakeful alertness. Biol. Psychiatry 1997; 41: 8891-8901.
32. Hetrick WP, Sandman CA, Bunney WE jr, Jin Y, Potkin SG, White MH. Gender differences in gating of the auditory evoked potential in normal subjects. Biol. Psychiatry 1996; 39: 151-158.
33. Erwin RJ, Mawhinney-Hee M, Gur RC, Gur RE. Midlatency auditory evoked responses in schizophrenia. Biol. Psychiatry 1991; 30: 5430-5442.
34. Knight RT, Scabini D, Woods DL, Clayworth C. The effects of lesions of superior temporal gyrus and inferior parietal lobe on temporal and vertex components of the human AEP. Electroencephal. Clin. Neurophysiol. 1988; 70: 499-509.
35. Reite M, Teak P, Zimmerman J, Davis K, Whalen J. Source location of a 50 msec latency auditory evoked field component. Electroencephal. Clin. Neurophysiol. 1988; 70: 490-498.
36. Amaral DG, Cowan MW. Evidence for a direct projection from the superior temporal gyrus to the enthorinal cortex in the monkey. J. Comp. Neurol. 1980; 189: 573-591.
37. Bickford-Wimer P, Nagamoto H, Johnson R, Adler LE, Egan M, Rose GM, Freedman R. Auditory sensory gating in hippocampal neuron: a model system in the rat. Biol. Psychiatry 1990; 27: 183-192.
38. Simpson GV, Knight RT. Multiple brain systems generating the rat auditory evoked potential: II. Dissociation of auditory cortex and nonlemniscal generator systems. Brain Res. 1993; 602: 251-263.
39. Vinogradova O. Functional organisation of the limbic system in the process of registration of information. W: Isaacson RL, Pribram KH, red. The hippocampus: neurophysiology and behavior. Vol. 1. New York, NY. Plenum Press; 1975, s. 3-69.
40. Luntz-Leybman V, Bickford PC, Freedman R. Cholinergic gating of response to auditory stimuli in rat hipocampus. Brain Res. 1992; 587: 130-136.
41. Freedman R, Wetmore C, Stromberg I, Leonard S, Olson L. A-bungarotoxin binding to hippocampal interneurons: immunocytochemical characterization and effect on growth factor expression. J. Neurosc. 1993; 13: 1965-1975.
42. Miller C, Freedman R. The activity of hippocampal interneurons and pyramidal cells during the response of the hippocampus to repeated auditory stimuli. Neurosc. 1995; 69: 371-381.
43. Schoepfer R, Conroy WG, Whiting P, Gore M, Lindstrom J. Brain-bungarotoxin binding protein cDNAs and MAbs reveal subtypes of this branch of the liganted ion channel gene superfamily. Neur. 1990; 5: 35-48.
44. Freedman R, Hall M, Adler LE, Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol. Psychiatry 1995; 38: 22-33.
45. Stevens KE, Freedman R, Collins AC, Hall M, Leonard S, Marks MJ, Rose GM. Genetic correlation of inhibitory gating of hippocampal auditory evoked response and alpha-bungarotoxin-binding nicotinic cholinergic receptors in inbred mouse strains. Neuropsychopharmacol. 1996; 15(2): 152-162.
46. Jessen F, Kucharski C, Fries T, Papassotiropoulos A, Hoenig K, Maier W, Heun R. Sensory gating deficit expressed by a disturbed suppression of the P50 event-related potential in patients with Alzheimer's disease. Am. J. Psychiatry 2001; 158(8): 1319-1321.
47. Braff DL, Geyer MA. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch. Gen. Psychiatry 1990; 47: 181-188.
48. Freedman R, Waldo M, Bickford-Wimer P, Nagamoto H. Elementary neuronal dysfunctions in schizophrenia. Schiz. Res. 1991; 4: 233-243.
49. Nagamoto HT, Adler LE, Waldo MC, Freedman R. Sensory gating in schizophrenics and normal controls: effect of changing stimulation interval. Biol. Psychiatry 1989; 25: 549-561.
50. Ward PB, Hoffer LD, Liebert BJ, Catts SV, O'Donnell M, Adler LE. Replication of a P50 auditory gating deficit in Australian patients with schizophrenia. Psychiatry Res. 1996; 64: 2121-2135.
51. Freedman R, Adler LE, Myles-Worsley M, Nagamoto HT, Miller C, Kisley M, McRae K, Cawthra E, Waldo M. Inhibitory gating of an evoked response to repeated auditory stimuli in schizophrenic and normal subjects. Human recordings, computer simulation, and an animal model. Arch. Gen. Psychiatry 1996; 53: 121114-121121.
52. Boutros NN, Zouridakis G, Overall J. Replication and extension of P50 findings in schizophrenia. Clin. Electroencephal. 1991; 22: 140-145.
53. Judd LL, McAdams L, Budnick B, Braff DL. Sensory gating deficits in schizophrenia: new results. Am. J. Psychiatry 1992; 149: 4488-4493.
54. Clementz BA, Geyer MA, Braff DL. Multiple site evaluation of P50 suppresion among schizophrenia and normal comparision subjects. Schizophr. Res. 1998; 30 (1): 71-80.
55. Erwin RJ, Turetsky BI, Moberg P, Gur RC, Gur RE. P50 abnormalities in schizophrenia: relationship to clinical and neuropsychological indices of attention. Schizophr. Res. 1998; 33(3): 157-167.
56. Franks RD, Adler LE, Waldo MC, Alpert J, Freedman R. Neurophysiological studies of sensory gating in mania: comparison with schizophrenia. Biol. Psychiatry 1983; 18: 989-1005.
57. Baker NJ, Staunton M, Adler LE, Gerhardt GA, Drebing C, Waldo M, Nagamoto H, Freedman R. Sensory gating deficits in psychiatric inpatients: relation to catecholamine metabolites in different diagnostic groups. Biol. Psychiatry 1990; 27: 5519-5528.
58. Baker N, Adler LE, Franks RD, Waldo M, Berry S, Nagamoto H, Muckle A, Freedman R. Neurophysiological assessment of sensory gating in psychiatric inpatients: comparison between schizophrenia and other diagnoses. Biol. Psychiatry 1987; 22: 5603-5617.
59. Boutros N, Zouridakis G, Rustin T, Peabody C, Warner D. The P50 component of the auditory evoked potential and subtypes of schizophrenia. Psychiatry Res. 1993; 47: 3243-3254.
60. Adler LE, Gerhardt GA, Franks R, Baker N, Nagamoto H, Drebing C, Freedman R. Sensory physiology and catecholamines in schizophrenia and mania. Psychiatric Res. 1989; 31: 297-309.
61. Benes FM, Vincent SL, Altsterberg O, Bird ED, SanGiovanni JP. Increased GABA-A receptor binding in superficial layers of cingulate cortex of schizophrenics. J. Neurosc. 1992; 12: 924-929.
62. Benes FM, McSparren J, Bird ED, SanGiovanni JP, Vincent SL. Deficits in small interneurons in prefrontal and cingulate corticies of schizophrenic and schizoaffective patients. Arch. Gen. Psychiatry 1991; 48: 996-1001.
63. Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE jr, Jones EG. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch. Gen. Psychiatry 1995; 52: 258-266.
64. Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K, Flach K, Nagamoto H, Bickford P, Leonard S, Freedman R. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr. Bull. 1998; 24: 2189-2202.
65. Leonard S, Adams C, Breese CR, Adler LE, Bickford P, Byerley W, Coon H, Griffith JM, Miller C, Myles-Worsley M, Nagamoto HT, Rollins Y, Stevens KE, Waldo M, Freedman R. Nicotinic receptor function in schizophrenia. Schizophr. Bull. 1996; 22: 3431-3445.
66. Adler LE, Hoffer LD, Wiser A, Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am. J. Psychiatry 1993; 150: 121856-121861.
67. Szymusiak R, Moriarity S, McGinty D. Excitation of basal forebrain neurons by pedunculopontine stimulation. Abstracts: Society for Neuroscience 1991, 345.
68. Griffith J, Hoffer LD, Adler LE, Zerbe GO, Freedman R. Effects of sound intensity on a midlalency evoked response to repeated auditory stimuli in schizophrenic and normal subjects. Psychophysiol. 1995; 32: 5460-5466.
69. Griffith JM, O'Neill JE, Petty F, Garver D, Young D, Freedman R. Nicotinic receptor desensitization and sensory gating deficits in schizophrenia. Biol. Psychiatry 1998; 44: 298-106.
70. Meehl PE. Schizotaxia, schizotypy, schizophrenia. Am. Psychol. 1962; 17: 827-838.
71. Chini B, Raimond E, Elgoyhen AB, Moralli D, Balzaretti M, Heinemann S. Molecular cloning and chromosomal localization of the human 7-nicotinic receptor subunit gene [CHRNA 7]. Genom. 1994; 19: 379-381.
72. Leonard S, Gault J, Moore T, Hopkins J, Robinson M, Olincy A, Adler LE, Cloninger CR, Kaufmann C.A., Tsuang M.T., Faraone S.V., Malaspina D., Svrakic D.M., Freedman R.: Further investigation of a chromosome 15 locus in schizophrenia: analysis of affected sibpairs from the NIMH Genetics Initiative. Am. J. Med. Genet. 1998; 81: 4308-4312.
73. Riley BP, Makoff A, Moguid-Carter M, Jenkins T, Williamson R, Collier D, Murray R. Haplotype transmission disequilibrium and evidence for linkage of the CHRNA 7 gene region to schizophrenia in Southern African Bantu families. Am. J. Med. Genet., 2000; 96: 196-201.
74. Stassen HH, Bridler R, Hagele S. Schizophrenia and smoking: evidence for common neurobiological basis? Am. J. Med. Genet. 2000; 96: 173-177.
75. Kaufmann CA, Suarez B, Malaspina D, Pepple J, Svrakic D, Markel PD, Meyer J, Zambuto CT, Schmitt K, Matise TC, Harkavy Friedman JM, Hampe C, Lee H, Shore D, Wynne D, Faraone SV, Tsuang MT, Cloninger CR. NIMH genetic initiative millenium 4chizophrenia consortium: linkage analysis of African-American pedigrees. Am. J. Med. Genet. 1998; 81 (4): 282-289.
76. Curtis L, Blouin JL, Radhakrishna U, Gehrig C, Lasseter VK, Wolyniec P, Nestadt G, Dombroski B, Kazazian HH, Pulver AE, Housman D, Bertrand D, Antonarakis SE. No evidence for linkage between schizophrenia and markers at chromosome 15q15-l4. Am. J. Med. Genet. 1999; 88: 2109-2112.
77. Neves-Pereira M, Bassett AS, Honer WG, Lang D, King NA, Kennedy JL. No evidence for linkage of the CHRNA 7 gene region in Canadian schizophrenia families. Am. J. Med. Genet. 1998; 81: 361-363.
78. Adler LE, Hoffer LJ, Griffith J, Waldo MC, Freedman R. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol. Psychiatry 1992; 32: 7607-7616.
79. Waldo MC, Carey G, Myles-Worsley M, Cawthra E, Adler LE, Nagamoto HT, Wender P, Byerley W, Plaetke R, Freedman R. Codistribution of a sensory gating deficit and schizophrenia in multi-affected families. Psychiatry Res. 1991; 39: 3257-3268.
80. Young DA, Waldo M, Rutledge JH 3rd, Freedman R. Heritability of inhibitory gating of the P50 auditory-evoked potential in monozygotic and dizygotic twins. Neuropsychobiol. 1996.
81. Cadenhead KS, Light GA, Geyer MA, Braff DL. Sensory gating deficits assessed by the P50 event-related potential in subjects with schizotypal personality disorder. Am. J. Psychiatry 2000; 157: 155-159.
82. de Bruin NM, Ellenbroek BA, van Luijtelaar EL, Cools AR, Stevens KE. Hippocampal and cortical sensory gating in rats: effects of quinpirole microinjections in nucleus accumbens core and shell. Neurosc. 2001; 105(1): 169-180.
83. Kathmann N, Engel RR. Sensory gating in normals and schizophrenics: a failure to find strong P50 suppresion in normals. Biol. Psychiatry 1990; 27: 1216-1226.
84. Light GA, Braff DL. The "incredible shrinking" P50 event-related potential. Biol. Psychiatry 1998; 43: 12918-12920.
85. Patterson JV, Jin Y, Gierczak M, Hetrick WP, Potkin S, Bunney WE jr, Sandman CA. Effects of temporal variability on P50 and the gating ratio in schizophrenia. Arch. Gen. Psychiatry 2000; 57: 57-64.
86. Jin Y, Potkin SG, Patterson JV, Sandman CA, Hetrick WP, Bunney WE. Effects of P50 temporal variability on sensory gating in schizophrenia. J. Psychiatry Res. 1997 May; 70: 271-281.
87. Waldo MC, Cawthra E, Adler LE, Dubester S, Staunton M, Nagamoto H, Baker N, Madison A, Simon J, Scherzinger A, Drebing C, Gerhardt G, Freedman R. Auditory sensory gating, hippocampal volume, and catecholamine metabolism in schizophrenics and their siblings. Schiz. Res. 1994; 12: 93-106.
88. Freedman R, Mirsky AF. Event related potentials: exogenous components. W: Nasrallah HA, red. Handbook of schizophrenia. Vol. 5. Amsterdam, London, New York, Tokyo: Elsevier; 1991, s. 71-90.
89. Griffith JM, Freedman R. Normalization of the auditory P50 gating deficit of schizophrenic patients after non-REM but not REM sleep. Psychiatry Res. 1995; 56: 3271-3278.
90. Jin Y, Bunney WE jr, Sandman CA, Patterson JV, Fleming K, Moenter JR. Is P50 suppression a measure of sensory gating in schizophrenia? Biol. Psychiatry 1998; 43: 873-878.
91. Oranje B, Gispen-de Wied CC, Verbaten MN, Kahn RS. Modulating sensory gating in healthy volunteers: The effects of ketamine and haloperidol. Biol. Psychiatry 2002; 52, 9: 887-895.
92. Nagamoto HT, Adler LE, Hea RA, Griffith JM, McRae KA, Freedman R. Gating of auditory P50 in schizophrenics: unique effects of clozapine. Biol. Psychiatry 1996; 40: 3181-3188.
93. Nagamoto HT, Adler LE, McRae KA, Huettl P, Cawthra E, Gerhardt G, Hea R, Griffith J. Auditory P50 in schizophrenics on clozapine: improved gating paralells clinical improvement and changes in plasma 3-methoxy-4- hydroxyphenylglycol. Neuropsychobiol. 1999; 39: 10-17.
94. Light GA, Geyer MA, Clementz BA, Cadenhead KS, Braff DL. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am. J. Psychiatry 2000; 157: 5767-5771.
95. Yee CM, Neuchterlein KH, Morris SE, White PM. P50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects. J. Abnorm. Psychol. 1998; 107: 691-698.
96. Adler LE, Cawthra EM, Nagamoto HT, MaRae KA, Waldo MC. Atypical antipsychotics differ in effect on P50 auditory sensory gating. Schiz. Res. 2003; 60: 1, supl. 248.